Taylor Vinters acts for Congenica as they secure £2.2 million funding

Congenica, a spin-out from the Sanger Wellcome Trust, has raised £2.2 million following a Series A round of financing, with Amaedeus Capital Partners and Cambridge Innovation Capital investing in the start-up.

Taylor Vinters advised the year-old start-up founded by leading geneticists in the funding round. Congenica have created a platform to screen for genetic mutations, to spot rare genetic disease in patients which may otherwise not be easily detected. These inherited, sometimes debilitating conditions are thought to affect 6% of the population, and the technology produced by Congenica has already been proven to detect previously undiagnosed conditions in children.

The company has now achieved £5 million in funding, opening the door for vital developments in the research, detection and treatment of rare genetic disorders.

Tom McGuire (partner) and Chris Keen (associate) advised on this deal. They both work in the Commercial Technology team at Taylor Vinters.